{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:37:20Z","timestamp":1789699040574,"version":"4.0.1"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Advances in pharmacogenomics have paved the way for personalized medicine. Cardiovascular diseases still represent the leading cause of mortality worldwide. This review aims to summarize the background, rationale, and evidence of pharmacogenomics in atherosclerosis, in particular, the use of antiplatelet and lipid-lowering drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Atherosclerotic disease is strongly influenced by the patient\u2019s genetic background. Randomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary heart disease undergoing percutaneous coronary intervention. Furthermore, there is growing evidence to support the association between some genetic variants and poor adherence to statin therapy, for example, due to the development of muscular symptoms. There is evidence for resistance to some drugs for the treatment of dyslipidemia, such as PCSK9 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Pharmacogenomics can potentially improve patient care by enabling individualized therapy and facilitating the development of novel therapeutic strategies for cardiovascular disease. This is particularly relevant in a field characterized by high morbidity and mortality. These advances may translate into improved clinical outcomes, reduced healthcare costs, and lower cardiovascular mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11883-026-01414-2","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:51:06Z","timestamp":1779353466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacogenomics of Atherosclerotic Plaque: Pathophysiological Background and Therapeutic Perspectives"],"prefix":"10.1007","volume":"28","author":[{"given":"Alfredo","family":"Mauriello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Correra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giallauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1414_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2147\/PGPM.S338601","volume":"15","author":"IG Asiimwe","year":"2022","unstructured":"Asiimwe IG, Pirmohamed M. Drug\u2013drug\u2013gene interactions in cardiovascular medicine. Pharmacogenomics Pers Med. 2022;15:879\u2013911. https:\/\/doi.org\/10.2147\/PGPM.S338601.","journal-title":"Pharmacogenomics Pers Med"},{"key":"1414_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.hlc.2018.09.006","volume":"28","author":"M Tibaut","year":"2019","unstructured":"Tibaut M, Caprnda M, Kubatka P, Sinkovi\u010d A, Valentova V, Filipova S, et al. Markers of atherosclerosis: part 2 \u2013 genetic and imaging markers. Heart Lung Circ. 2019;28:678\u201389. https:\/\/doi.org\/10.1016\/j.hlc.2018.09.006.","journal-title":"Heart Lung Circ"},{"key":"1414_CR3","doi-asserted-by":"publisher","first-page":"119131","DOI":"10.1016\/j.atherosclerosis.2025.119131","volume":"404","author":"I Damiani","year":"2025","unstructured":"Damiani I, Solberg EH, Iyer M, Cheng P, Weldy CS, Kim JB. Environmental pollutants and atherosclerosis: epigenetic mechanisms linking genetic risk and disease. Atherosclerosis. 2025;404:119131. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119131.","journal-title":"Atherosclerosis"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1570161116666180206111725","volume":"17","author":"A Peterlin","year":"2018","unstructured":"Peterlin A, Petrovi\u010d D, Peterlin B. Screening for rare genetic variants associated with atherosclerosis: opportunity for personalized medicine. Curr Vasc Pharmacol. 2018;17:25\u20138. https:\/\/doi.org\/10.2174\/1570161116666180206111725.","journal-title":"Curr Vasc Pharmacol"},{"key":"1414_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-019-0135-8","volume":"20","author":"A Radhakrishnan","year":"2020","unstructured":"Radhakrishnan A, Kuppusamy G, Ponnusankar S, Shanmukhan NK. Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery. Pharmacogenomics J. 2020;20:1\u201318. https:\/\/doi.org\/10.1038\/s41397-019-0135-8.","journal-title":"Pharmacogenomics J"},{"key":"1414_CR6","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.3390\/genes14112057","volume":"14","author":"A Mauriello","year":"2023","unstructured":"Mauriello A, Ascrizzi A, Molinari R, Falco L, Caturano A, D\u2019Andrea A, et al. Pharmacogenomics of cardiovascular drugs for atherothrombotic, thromboembolic and atherosclerotic risk. Genes (Basel). 2023;14:2057. https:\/\/doi.org\/10.3390\/genes14112057.","journal-title":"Genes (Basel)"},{"key":"1414_CR7","doi-asserted-by":"publisher","unstructured":"Jebari-Benslaiman S, Galicia-Garc\u00eda U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23063346","DOI":"10.3390\/ijms23063346"},{"key":"1414_CR8","doi-asserted-by":"publisher","unstructured":"Insull W. The pathology of atherosclerosis: Plaque development and plaque responses to medical treatment. Am J Med. 2009;122. https:\/\/doi.org\/10.1016\/j.amjmed.2008.10.013","DOI":"10.1016\/j.amjmed.2008.10.013"},{"key":"1414_CR9","doi-asserted-by":"publisher","unstructured":"Bor\u00e9n J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016: 473\u201383. https:\/\/doi.org\/10.1097\/MOL.0000000000000330","DOI":"10.1097\/MOL.0000000000000330"},{"key":"1414_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/jcm14051652","volume":"14","author":"A Mauriello","year":"2025","unstructured":"Mauriello A, Correra A, Maratea AC, Caturano A, Liccardo B, Perrone MA, et al. Serum lipids, inflammation, and the risk of atrial fibrillation: pathophysiological links and clinical evidence. J Clin Med. 2025;14:1652. https:\/\/doi.org\/10.3390\/jcm14051652.","journal-title":"J Clin Med"},{"key":"1414_CR11","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1161\/01.ATV.20.6.1572","volume":"20","author":"V Llorente-Cort\u00e9s","year":"2000","unstructured":"Llorente-Cort\u00e9s V, Mart\u00ednez-Gonz\u00e1lez J, Badimon L. LDL receptor-related protein mediates uptake of aggregated LDL in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:1572\u20139. https:\/\/doi.org\/10.1161\/01.ATV.20.6.1572.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1414_CR12","doi-asserted-by":"publisher","unstructured":"Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015: 161\u201372. https:\/\/doi.org\/10.1016\/j.cell.2015.01.036","DOI":"10.1016\/j.cell.2015.01.036"},{"key":"1414_CR13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/LIFE13091888","volume":"13","author":"V Russo","year":"2023","unstructured":"Russo V, Falco L, Tessitore V, Mauriello A, Catapano D, Napolitano N, et al. Anti-inflammatory and anticancer effects of anticoagulant therapy in patients with malignancy. Life. 2023;13:1888. https:\/\/doi.org\/10.3390\/LIFE13091888.","journal-title":"Life"},{"key":"1414_CR14","doi-asserted-by":"publisher","unstructured":"Mauriello A, Maratea AC, Fonderico C, Quagliariello V, Maurea F, Maurea N. Factor XI and cancer: physiopathological linkage and clinical perspectives. J Clin Med. 2025;14:6341. https:\/\/doi.org\/10.3390\/jcm14176341.","DOI":"10.3390\/jcm14176341"},{"key":"1414_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","volume":"114","author":"JF Bentzon","year":"2014","unstructured":"Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res. 2014;114:1852\u201366. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302721.","journal-title":"Circ Res"},{"key":"1414_CR16","doi-asserted-by":"publisher","unstructured":"Asada Y, Yamashita A, Sato Y, Hatakeyama K. Pathophysiology of atherothrombosis: mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int. 2020:309\u201322. https:\/\/doi.org\/10.1111\/pin.12921","DOI":"10.1111\/pin.12921"},{"key":"1414_CR17","doi-asserted-by":"publisher","unstructured":"Anlamlert W, Lenbury Y, Bell J. Modeling fibrous cap formation in atherosclerotic plaque development: stability and oscillatory behavior. Adv Differ Equ. 2017;2017. https:\/\/doi.org\/10.1186\/s13662-017-1252-9","DOI":"10.1186\/s13662-017-1252-9"},{"key":"1414_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37727","author":"Y Yu","year":"2024","unstructured":"Yu Y, Cai Y, Yang F, Yang Y, Cui Z, Shi D, et al. Vascular smooth muscle cell phenotypic switching in atherosclerosis. Heliyon. 2024. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37727.","journal-title":"Heliyon"},{"key":"1414_CR19","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/biomedicines12122720","volume":"12","author":"A Mauriello","year":"2024","unstructured":"Mauriello A, Correra A, Molinari R, Del Vecchio GE, Tessitore V, D\u2019Andrea A, et al. Mitochondrial dysfunction in atrial fibrillation: the need for a strong pharmacological approach. Biomedicines. 2024;12:2720. https:\/\/doi.org\/10.3390\/biomedicines12122720.","journal-title":"Biomedicines"},{"key":"1414_CR20","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-14-0621","author":"F De Paoli","year":"2014","unstructured":"De Paoli F, Staels B, Chinetti-Gbaguidi G, Japanese Circulation Society. Macrophage phenotypes and their modulation in atherosclerosis. Circ J. 2014. https:\/\/doi.org\/10.1253\/circj.CJ-14-0621.","journal-title":"Circ J"},{"key":"1414_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/ph17040447","volume":"17","author":"V Russo","year":"2024","unstructured":"Russo V, Napolitano N, Ascrizzi A, Leonardi S, Pisacane F, Di Micco P, et al. The lipid-lowering efficacy of a nutraceutical combination including leucoselect phytosome, red yeast rice, policosanol and folic acid in dyslipidaemia patients: real-world insights. Pharmaceuticals. 2024;17:447. https:\/\/doi.org\/10.3390\/ph17040447.","journal-title":"Pharmaceuticals"},{"key":"1414_CR22","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone","year":"2016","unstructured":"Gimbrone MA, Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res Lippincott Williams and Wilkins. 2016;118:620\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306301.","journal-title":"Circ Res Lippincott Williams and Wilkins"},{"key":"1414_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/antiox14050522","volume":"14","author":"A Mauriello","year":"2025","unstructured":"Mauriello A, Del GC, Del VGE, Correra A, Maratea AC, Grieco M, et al. Takotsubo syndrome and oxidative stress: physiopathological linkage and future perspectives. Antioxidants. 2025;14:522. https:\/\/doi.org\/10.3390\/antiox14050522.","journal-title":"Antioxidants"},{"key":"1414_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1074\/jbc.M307528200","volume":"279","author":"ME Davis","year":"2004","unstructured":"Davis ME, Grumbach IM, Fukai T, Cutchins A, Harrison DG. Shear Stress regulates endothelial nitric-oxide synthase promoter activity through nuclear factor \u03baB binding. J Biol Chem. 2004;279:163\u20138. https:\/\/doi.org\/10.1074\/jbc.M307528200.","journal-title":"J Biol Chem"},{"key":"1414_CR25","doi-asserted-by":"publisher","unstructured":"Wong ND, Budoff MJ, Ferdinand K, Graham IM, Michos ED, Reddy T, et al. Atherosclerotic cardiovascular disease risk assessment: an American Society for Preventive Cardiology clinical practice statement. Am J Prev Cardiol. 2022;10. https:\/\/doi.org\/10.1016\/j.ajpc.2022.100335","DOI":"10.1016\/j.ajpc.2022.100335"},{"key":"1414_CR26","doi-asserted-by":"publisher","unstructured":"Visseren F, Mach F, Smulders YM, Carballo D, Koskinas KC, B\u00e4ck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"1414_CR27","doi-asserted-by":"publisher","unstructured":"Vernon ST, Sci M, Coffey S, D\u2019souza M, Chow CK, Kilian J, et al. ST-Segment-Elevation Myocardial Infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes?. https:\/\/doi.org\/10.1161\/JAHA","DOI":"10.1161\/JAHA"},{"key":"1414_CR28","doi-asserted-by":"publisher","unstructured":"Tada H, Takamura M, Kawashiri MA. Familial hypercholesterolemia: A narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag. 2021:59\u201367. https:\/\/doi.org\/10.2147\/VHRM.S266249","DOI":"10.2147\/VHRM.S266249"},{"key":"1414_CR29","doi-asserted-by":"publisher","unstructured":"McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2019;8. https:\/\/doi.org\/10.1161\/JAHA.119.013225","DOI":"10.1161\/JAHA.119.013225"},{"key":"1414_CR30","doi-asserted-by":"publisher","unstructured":"Santos RD, Cuchel M. LDL-C-lowering therapies for adults and children with homozygous familial hypercholesterolemia: challenges and successes. Circulation. 2024:363\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067241","DOI":"10.1161\/CIRCULATIONAHA.123.067241"},{"key":"1414_CR31","doi-asserted-by":"publisher","unstructured":"Mauriello A, Correra A, Maratea AC, Benfari G, Ilardi F, Giugliano G, et al. Radiation-Induced Carotid Artery Disease: Pathogenesis, Diagnosis and Management. Diagnostics. 2026;16:841 https:\/\/doi.org\/10.3390\/diagnostics16060841","DOI":"10.3390\/diagnostics16060841"},{"key":"1414_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.120.315928","volume":"126","author":"KG Aragam","year":"2020","unstructured":"Aragam KG, Natarajan P. Polygenic scores to assess atherosclerotic cardiovascular disease risk: clinical perspectives and basic implications. Circ Res. 2020;126:1159\u201377. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.315928.","journal-title":"Circ Res"},{"key":"1414_CR33","doi-asserted-by":"publisher","unstructured":"Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 2009:212\u20139. https:\/\/doi.org\/10.1016\/j.gde.2009.04.010","DOI":"10.1016\/j.gde.2009.04.010"},{"key":"1414_CR34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/bioinformatics\/btw745","volume":"33","author":"HC So","year":"2017","unstructured":"So HC, Sham PC, Valencia A. Exploring the predictive power of polygenic scores derived from genome-wide association studies: a study of 10 complex traits. Bioinformatics. 2017;33:886\u201392. https:\/\/doi.org\/10.1093\/bioinformatics\/btw745.","journal-title":"Bioinformatics"},{"key":"1414_CR35","doi-asserted-by":"crossref","unstructured":"Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events abstract. N Engl J Med. 2008. www.nejm.org","DOI":"10.1016\/j.jvs.2008.04.037"},{"key":"1414_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jacc.2018.07.079","volume":"72","author":"M Inouye","year":"2018","unstructured":"Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol Elsevier USA. 2018;72:1883\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.079.","journal-title":"J Am Coll Cardiol Elsevier USA"},{"key":"1414_CR37","doi-asserted-by":"publisher","unstructured":"Natarajan P. Polygenic risk scoring for coronary heart disease: the first risk factor. J Am Coll Cardiol. 2018:1894\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1041","DOI":"10.1016\/j.jacc.2018.08.1041"},{"key":"1414_CR38","doi-asserted-by":"publisher","unstructured":"Pillutla V, Aragam KG. Polygenic scores in real-world cardiovascular risk prediction: the path forward for assessing worth? Eur Heart J. 2024:3161\u20133. https:\/\/doi.org\/10.1093\/eurheartj\/ehae442","DOI":"10.1093\/eurheartj\/ehae442"},{"key":"1414_CR39","doi-asserted-by":"publisher","unstructured":"Christiansen MK, Nissen L, Winther S, M\u00f8ller PL, Frost L, Johansen JK, et al. Genetic risk of coronary artery disease, features of atherosclerosis, and coronary plaque burden. J Am Heart Assoc. 2020;9. https:\/\/doi.org\/10.1161\/JAHA.119.014795","DOI":"10.1161\/JAHA.119.014795"},{"key":"1414_CR40","doi-asserted-by":"publisher","first-page":"e002352","DOI":"10.1161\/CIRCGEN.118.002352","volume":"11","author":"MG Levin","year":"2018","unstructured":"Levin MG, Kember RL, Judy R, Birtwell D, Williams H, Arany Z, et al. Genomic Risk Stratification Predicts All-Cause Mortality After Cardiac Catheterization. Circ Genom Precis Med. 2018;11:e002352. https:\/\/doi.org\/10.1161\/CIRCGEN.118.002352.","journal-title":"Circ Genom Precis Med"},{"key":"1414_CR41","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/eurheartj\/ehae649","volume":"46","author":"H Schunkert","year":"2025","unstructured":"Schunkert H, Di Angelantonio E, Inouye M, Patel RS, Ripatti S, Widen E, et al. Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease a clinical consensus statement of the ESC Council on Cardiovascular Genomics, the ESC Cardiovascular Risk Collaboration, and the European Association of Preventive Cardiology. Eur Heart J Oxford University Press. 2025;46:1372\u201383. https:\/\/doi.org\/10.1093\/eurheartj\/ehae649.","journal-title":"Eur Heart J Oxford University Press"},{"key":"1414_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","volume":"73","author":"N Ferri","year":"2013","unstructured":"Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681\u2013709. https:\/\/doi.org\/10.1007\/s40265-013-0126-z.","journal-title":"Drugs"},{"key":"1414_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ANTIOX12061185","author":"L Falco","year":"2023","unstructured":"Falco L, Tessitore V, Ciccarelli G, Malvezzi M, D\u2019Andrea A, Imbalzano E, et al. Antioxidant properties of oral antithrombotic therapies in atherosclerotic disease and atrial fibrillation. Antioxidants. 2023. https:\/\/doi.org\/10.3390\/ANTIOX12061185.","journal-title":"Antioxidants"},{"key":"1414_CR44","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112:959\u201367. https:\/\/doi.org\/10.1002\/cpt.2526.","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR45","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.jacc.2010.12.047","volume":"57","author":"G Campo","year":"2011","unstructured":"Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. J Am Coll Cardiol. 2011;57:2474\u201383. https:\/\/doi.org\/10.1016\/j.jacc.2010.12.047.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1414_CR46","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849. https:\/\/doi.org\/10.1001\/jama.2009.1232.","journal-title":"JAMA"},{"key":"1414_CR47","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"D Trenk","year":"2008","unstructured":"Trenk D, Hochholzer W, Fromm MF, Chialda L-E, Pahl A, Valina CM, et al. <article-title update=\"added\">Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925\u201334. https:\/\/doi.org\/10.1016\/j.jacc.2007.12.056.","journal-title":"J Am Coll Cardiol"},{"key":"1414_CR48","doi-asserted-by":"publisher","unstructured":"Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306. https:\/\/doi.org\/10.1001\/jama.2011.1703","DOI":"10.1001\/jama.2011.1703"},{"key":"1414_CR49","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","volume":"379","author":"JD Roberts","year":"2012","unstructured":"Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet. 2012;379:1705\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(12)60161-5.","journal-title":"Lancet"},{"issue":"24","key":"1414_CR50","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1001\/jama.2011.1880","volume":"306","author":"MV Holmes","year":"2011","unstructured":"Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events. JAMA. 2011;306:2704. https:\/\/doi.org\/10.1001\/jama.2011.1880.","journal-title":"JAMA"},{"issue":"16","key":"1414_CR51","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA. 2010;304:1821. https:\/\/doi.org\/10.1001\/jama.2010.1543.","journal-title":"JAMA"},{"key":"1414_CR52","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"key":"1414_CR53","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"key":"1414_CR54","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","volume":"376","author":"L Wallentin","year":"2010","unstructured":"Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(10)61274-3.","journal-title":"Lancet"},{"key":"1414_CR55","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.jacc.2018.02.029","volume":"71","author":"FM Notarangelo","year":"2018","unstructured":"Notarangelo FM, Maglietta G, Bevilacqua P, Cereda M, Merlini PA, Villani GQ, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes. J Am Coll Cardiol. 2018;71:1869\u201377. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.029.","journal-title":"J Am Coll Cardiol"},{"key":"1414_CR56","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van \u2019t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y 12 inhibitors in primary PCI. N Engl J Med. 2019;381:1621\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1907096.","journal-title":"N Engl J Med"},{"key":"1414_CR57","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.2020.12443","volume":"324","author":"NL Pereira","year":"2020","unstructured":"Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention. JAMA. 2020;324:761. https:\/\/doi.org\/10.1001\/jama.2020.12443.","journal-title":"JAMA"},{"key":"1414_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 Loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316:70. https:\/\/doi.org\/10.1001\/jama.2016.8662.","journal-title":"JAMA"},{"key":"1414_CR59","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00228-022-03346-7","volume":"78","author":"S Huang","year":"2022","unstructured":"Huang S, Yang S, Ly S, Yoo RH, Lo-Ciganic W-H, Eadon MT, et al. Clinical non-effectiveness of clopidogrel use for peripheral artery disease in patients with CYP2C19 polymorphisms: a systematic review. Eur J Clin Pharmacol. 2022;78:1217\u201325. https:\/\/doi.org\/10.1007\/s00228-022-03346-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"1414_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2022.08.001","volume":"254","author":"J Kranendonk","year":"2022","unstructured":"Kranendonk J, Willems L, van der Vijver-Coppen RJ, Coenen M, Adang E, Donders R, et al. CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). Am Heart J. 2022;254:141\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2022.08.001.","journal-title":"Am Heart J"},{"key":"1414_CR61","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1253\/circj.CJ-20-0254","volume":"84","author":"Y Sawayama","year":"2020","unstructured":"Sawayama Y, Yamamoto T, Tomita Y, Asada K, Yagi N, Fukuyama M, et al. Comparison between clopidogrel and prasugrel associated with CYP2C19 genotypes in patients receiving percutaneous coronary intervention in a Japanese population. Circ J. 2020;84:1575\u201381. https:\/\/doi.org\/10.1253\/circj.CJ-20-0254.","journal-title":"Circ J"},{"key":"1414_CR62","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","volume":"376","author":"JL Mega","year":"2010","unstructured":"Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON\u2013TIMI 38 trial: a pharmacogenetic analysis. The Lancet. 2010;376:1312\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(10)61273-1.","journal-title":"The Lancet"},{"key":"1414_CR63","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/eurheartj\/ehv116","volume":"36","author":"C Varenhorst","year":"2015","unstructured":"Varenhorst C, Eriksson N, Johansson \u00c5, Barratt BJ, Hagstr\u00f6m E, \u00c5kerblom A, et al. Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. Eur Heart J. 2015;36:1901\u201312. https:\/\/doi.org\/10.1093\/eurheartj\/ehv116.","journal-title":"Eur Heart J"},{"key":"1414_CR64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","volume":"110","author":"JR Vane","year":"2003","unstructured":"Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255\u20138. https:\/\/doi.org\/10.1016\/S0049-3848(03)00379-7.","journal-title":"Thromb Res"},{"key":"1414_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/pgs-2019-0133","volume":"21","author":"M Ferreira","year":"2020","unstructured":"Ferreira M, Freitas-Silva M, Assis J, Pinto R, Nunes JP, Medeiros R. The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics. 2020;21:125\u201340. https:\/\/doi.org\/10.2217\/pgs-2019-0133.","journal-title":"Pharmacogenomics"},{"key":"1414_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","volume":"141","author":"CN Floyd","year":"2014","unstructured":"Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141:69\u201378. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.08.005.","journal-title":"Pharmacol Ther"},{"key":"1414_CR67","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1742-1241.2007.01344.x","volume":"61","author":"T Goodman","year":"2007","unstructured":"Goodman T, Sharma P, Ferro A. The genetics of aspirin resistance. Int J Clin Pract. 2007;61:826\u201334. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01344.x.","journal-title":"Int J Clin Pract"},{"key":"1414_CR68","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/eurheartj\/ehn562","volume":"30","author":"W Kuliczkowski","year":"2008","unstructured":"Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2008;30:426\u201335. https:\/\/doi.org\/10.1093\/eurheartj\/ehn562.","journal-title":"Eur Heart J"},{"key":"1414_CR69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5551\/jat.14092","volume":"20","author":"X Yi","year":"2013","unstructured":"Yi X, Zhou Q, Lin J, Chi L, Han Z. Platelet response to aspirin in Chinese stroke patients is independent of genetic polymorphisms of COX-1 C50T and COX-2 G765C. J Atheroscler Thromb. 2013;20:65\u201372. https:\/\/doi.org\/10.5551\/jat.14092.","journal-title":"J Atheroscler Thromb"},{"key":"1414_CR70","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1160\/TH05-07-0516","volume":"95","author":"A Lep\u00e4ntalo","year":"2006","unstructured":"Lep\u00e4ntalo A, Mikkelsson J, Res\u00e9ndiz J, Viiri L, Backman J, Kankuri E, et al. Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost. 2006;95:253\u20139. https:\/\/doi.org\/10.1160\/TH05-07-0516.","journal-title":"Thromb Haemost"},{"key":"1414_CR71","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11239-012-0777-8","volume":"35","author":"V Sharma","year":"2013","unstructured":"Sharma V, Kaul S, Al-Hazzani A, Alshatwi AA, Jyothy A, Munshi A. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis. 2013;35:95\u20139. https:\/\/doi.org\/10.1007\/s11239-012-0777-8.","journal-title":"J Thromb Thrombolysis"},{"key":"1414_CR72","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1161\/01.ATV.0000030340.80207.C5","volume":"22","author":"A Papafili","year":"2002","unstructured":"Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, et al. Common promoter variant in cyclooxygenase-2 represses gene expression. Arterioscler Thromb Vasc Biol. 2002;22:1631\u20136. https:\/\/doi.org\/10.1161\/01.ATV.0000030340.80207.C5.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1414_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.22331","author":"H Wang","year":"2018","unstructured":"Wang H, Sun X, Dong W, Cai X, Zhou Y, Zhang Y, et al. Association of GPI a and COX\u20102 gene polymorphism with aspirin resistance. J Clin Lab Anal. 2018. https:\/\/doi.org\/10.1002\/jcla.22331.","journal-title":"J Clin Lab Anal"},{"key":"1414_CR74","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1046\/j.1365-2141.2000.02267.x","volume":"110","author":"A Szczeklik","year":"2000","unstructured":"Szczeklik A, Undas A, Sanak M, Fro\u0142ow M, W\u0119grzyn W. Relationship between bleeding time, aspirin and the PlA1\/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol. 2000;110:965\u20137. https:\/\/doi.org\/10.1046\/j.1365-2141.2000.02267.x.","journal-title":"Br J Haematol"},{"key":"1414_CR75","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","volume":"66","author":"T Goodman","year":"2008","unstructured":"Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66:222\u201332. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03183.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1414_CR76","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/ATVBAHA.108.168971","volume":"28","author":"JE Herrera-Galeano","year":"2008","unstructured":"Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008;28:1484\u201390. https:\/\/doi.org\/10.1161\/ATVBAHA.108.168971.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1414_CR77","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/cpt.1959","volume":"108","author":"JP Lewis","year":"2020","unstructured":"Lewis JP, Riaz M, Xie S, Polekhina G, Wolfe R, Nelson M, et al. Genetic variation in PEAR1, cardiovascular outcomes and effects of aspirin in a healthy elderly population. Clin Pharmacol Ther. 2020;108:1289\u201398. https:\/\/doi.org\/10.1002\/cpt.1959.","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR78","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","volume":"203","author":"DI Chasman","year":"2009","unstructured":"Chasman DI, Shiffman D, Zee RYL, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.07.019.","journal-title":"Atherosclerosis"},{"key":"1414_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14796678.1.2.191","volume":"1","author":"I Zineh","year":"2005","unstructured":"Zineh I. HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice. Future Cardiol. 2005;1:191\u2013206. https:\/\/doi.org\/10.1517\/14796678.1.2.191.","journal-title":"Future Cardiol"},{"key":"1414_CR80","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3390\/life15111749","volume":"15","author":"A Mauriello","year":"2025","unstructured":"Mauriello A, Correra A, Maratea AC, Fonderico C, Amata A, Cetoretta V, et al. Protective role of lipid-lowering drugs in breast cancer: effects on cancer incidence and cardiotoxicity. Life. 2025;15:1749. https:\/\/doi.org\/10.3390\/life15111749.","journal-title":"Life"},{"key":"1414_CR81","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jacc.2007.10.017","volume":"51","author":"OA Iakoubova","year":"2008","unstructured":"Iakoubova OA, Sabatine MS, Rowland CM, Tong CH, Catanese JJ, Ranade K, et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes. J Am Coll Cardiol. 2008;51:449\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2007.10.017.","journal-title":"J Am Coll Cardiol"},{"key":"1414_CR82","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/CIRCULATIONAHA.108.773267","volume":"118","author":"MW Medina","year":"2008","unstructured":"Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008;118:355\u201362. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.773267.","journal-title":"Circulation"},{"key":"1414_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2009.54","volume":"10","author":"SPR Romaine","year":"2010","unstructured":"Romaine SPR, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2010;10:1\u201311. https:\/\/doi.org\/10.1038\/tpj.2009.54.","journal-title":"Pharmacogenomics J"},{"key":"1414_CR84","doi-asserted-by":"publisher","unstructured":"SLCO1B1 variants and statin-induced myopathy \u2014 a genomewide study. N Engl J Med. 2008;359:789\u201399. https:\/\/doi.org\/10.1056\/NEJMoa0801936","DOI":"10.1056\/NEJMoa0801936"},{"key":"1414_CR85","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2010.06.022","volume":"56","author":"TL Assimes","year":"2010","unstructured":"Assimes TL, H\u00f3lm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010;56:1552\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2010.06.022.","journal-title":"J Am Coll Cardiol"},{"key":"1414_CR86","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/sj.tpj.6500328","volume":"5","author":"JF Thompson","year":"2005","unstructured":"Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 2005;5:352\u20138. https:\/\/doi.org\/10.1038\/sj.tpj.6500328.","journal-title":"Pharmacogenomics J"},{"key":"1414_CR87","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","volume":"210","author":"A Ghatak","year":"2010","unstructured":"Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337\u201343. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.11.033.","journal-title":"Atherosclerosis"},{"key":"1414_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11584380-000000000-00000","volume":"34","author":"SDS Maggo","year":"2011","unstructured":"Maggo SDS, Kennedy MA, Clark DWJ. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf. 2011;34:1\u201319. https:\/\/doi.org\/10.2165\/11584380-000000000-00000.","journal-title":"Drug Saf"},{"key":"1414_CR89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/0091270006295063","volume":"47","author":"K Kim","year":"2007","unstructured":"Kim K, Park P, Lee O, Kang D, Park J. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol. 2007;47:87\u201393. https:\/\/doi.org\/10.1177\/0091270006295063.","journal-title":"J Clin Pharmacol"},{"key":"1414_CR90","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/clpt.2014.55","volume":"96","author":"N Tsamandouras","year":"2014","unstructured":"Tsamandouras N, Dickinson G, Guo Y, Hall S, Rostami-Hodjegan A, Galetin A, et al. Identification of the Effect of Multiple Polymorphisms on the Pharmacokinetics of Simvastatin and Simvastatin Acid Using a Population-Modeling Approach. Clin Pharmacol Ther. 2014;96:90\u2013100. https:\/\/doi.org\/10.1038\/clpt.2014.55.","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR91","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/tpj.2010.28","volume":"11","author":"D Wang","year":"2011","unstructured":"Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11:274\u201386. https:\/\/doi.org\/10.1038\/tpj.2010.28.","journal-title":"Pharmacogenomics J"},{"key":"1414_CR92","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","volume":"74","author":"J Kirchheiner","year":"2003","unstructured":"Kirchheiner J. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (\u2212)-3s,5r-fluvastatin and (+)-3r,5s-fluvastatin in healthy volunteers. Clin Pharmacol Ther. 2003;74:186\u201394. https:\/\/doi.org\/10.1016\/S0009-9236(03)00121-8.","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR93","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/FPC.0000000000000079","volume":"24","author":"JP Kitzmiller","year":"2014","unstructured":"Kitzmiller JP, Luzum JA, Baldassarre D, Krauss RM, Medina MW. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenet Genomics. 2014;24:486\u201391. https:\/\/doi.org\/10.1097\/FPC.0000000000000079.","journal-title":"Pharmacogenet Genomics"},{"key":"1414_CR94","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1073\/pnas.0500269102","volume":"102","author":"M Garcia-Calvo","year":"2005","unstructured":"Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci. 2005;102:8132\u20137. https:\/\/doi.org\/10.1073\/pnas.0500269102.","journal-title":"Proc Natl Acad Sci"},{"key":"1414_CR95","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.2165\/00003495-200262160-00002","volume":"62","author":"T Sudhop","year":"2002","unstructured":"Sudhop T, von Bergmann K. Cholesterol Absorption Inhibitors for the Treatment of Hypercholesterolaemia. Drugs. 2002;62:2333\u201347. https:\/\/doi.org\/10.2165\/00003495-200262160-00002.","journal-title":"Drugs"},{"key":"1414_CR96","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/FPC.0b013e3282fe9a2c","volume":"18","author":"S Oswald","year":"2008","unstructured":"Oswald S, K\u00f6nig J, L\u00fctjohann D, Giessmann T, Kroemer HK, Rimmbach C, et al. Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics. 2008;18:559\u201368. https:\/\/doi.org\/10.1097\/FPC.0b013e3282fe9a2c.","journal-title":"Pharmacogenet Genomics"},{"key":"1414_CR97","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/MOL.0b013e3280555083","volume":"18","author":"G Schmitz","year":"2007","unstructured":"Schmitz G, Schmitz-M\u0105dry A, Ugocsai P. Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy. Curr Opin Lipidol. 2007;18:164\u201373. https:\/\/doi.org\/10.1097\/MOL.0b013e3280555083.","journal-title":"Curr Opin Lipidol"},{"key":"1414_CR98","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.clpt.2005.11.004","volume":"79","author":"S Oswald","year":"2006","unstructured":"Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, et al. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate\u2013glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006;79:206\u201317. https:\/\/doi.org\/10.1016\/j.clpt.2005.11.004.","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR99","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.atherosclerosis.2011.07.126","volume":"219","author":"MM Hoffmann","year":"2011","unstructured":"Hoffmann MM, M\u00e4rz W, Genser B, Drechsler C, Wanner C. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis. 2011;219:659\u201362. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.07.126.","journal-title":"Atherosclerosis"},{"key":"1414_CR100","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1399-0004.2004.00388.x","volume":"67","author":"J Wang","year":"2005","unstructured":"Wang J, Williams C, Hegele R. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet. 2005;67:175\u20137. https:\/\/doi.org\/10.1111\/j.1399-0004.2004.00388.x.","journal-title":"Clin Genet"},{"key":"1414_CR101","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1476-511X-4-16","volume":"4","author":"RA Hegele","year":"2005","unstructured":"Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis. 2005;4:16. https:\/\/doi.org\/10.1186\/1476-511X-4-16.","journal-title":"Lipids Health Dis"},{"key":"1414_CR102","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ygeno.2005.08.007","volume":"86","author":"JS Simon","year":"2005","unstructured":"Simon JS, Karnoub MC, Devlin DJ, Arreaza MG, Qiu P, Monks SA, et al. Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment. Genomics. 2005;86:648\u201356. https:\/\/doi.org\/10.1016\/j.ygeno.2005.08.007.","journal-title":"Genomics"},{"key":"1414_CR103","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.2174\/1381612824666181010144823","volume":"24","author":"AN Tsouka","year":"2019","unstructured":"Tsouka AN, Tellis CC, Tselepis AD. Pharmacology of PCSK9 inhibitors: current status and future perspectives. Curr Pharm Des. 2019;24:3622\u201333. https:\/\/doi.org\/10.2174\/1381612824666181010144823.","journal-title":"Curr Pharm Des"},{"key":"1414_CR104","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"1414_CR105","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"1414_CR106","doi-asserted-by":"publisher","first-page":"6728","DOI":"10.12998\/wjcc.v10.i19.6728","volume":"10","author":"L Yang","year":"2022","unstructured":"Yang L, Xiao Y-Y, Shao L, Ouyang C-S, Hu Y, Li B, et al. Proprotein convertase subtilisin\/kexin type 9 inhibitor non responses in an adult with a history of coronary revascularization: a case report. World J Clin Cases. 2022;10:6728\u201335. https:\/\/doi.org\/10.12998\/wjcc.v10.i19.6728.","journal-title":"World J Clin Cases"},{"key":"1414_CR107","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1074\/jbc.M116.769430","volume":"292","author":"D Susan-Resiga","year":"2017","unstructured":"Susan-Resiga D, Girard E, Kiss RS, Essalmani R, Hamelin J, Asselin M-C, et al. The proprotein convertase subtilisin\/kexin type 9-resistant R410S low density lipoprotein receptor mutation. J Biol Chem. 2017;292:1573\u201390. https:\/\/doi.org\/10.1074\/jbc.M116.769430.","journal-title":"J Biol Chem"},{"key":"1414_CR108","doi-asserted-by":"publisher","first-page":"103953","DOI":"10.1016\/j.jaccas.2025.103953","volume":"30","author":"M Pindwarawala","year":"2025","unstructured":"Pindwarawala M, Bose S, Brunham LR. Apparent Nonresponse to PCSK9 inhibition in a patient with heterozygous familial hypercholesterolemia due to PCSK9 gene duplication. JACC Case Rep. 2025;30:103953. https:\/\/doi.org\/10.1016\/j.jaccas.2025.103953.","journal-title":"JACC Case Rep"},{"key":"1414_CR109","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1913805.","journal-title":"N Engl J Med"},{"key":"1414_CR110","doi-asserted-by":"publisher","first-page":"11739","DOI":"10.3390\/ijms241411739","volume":"24","author":"A Di Costanzo","year":"2023","unstructured":"Di Costanzo A, Indolfi C, Sorrentino S, Esposito G, Spaccarotella CAM. The effects of statins, ezetimibe, PCSK9-inhibitors, inclisiran, and icosapent ethyl on platelet function. Int J Mol Sci. 2023;24:11739. https:\/\/doi.org\/10.3390\/ijms241411739.","journal-title":"Int J Mol Sci"},{"key":"1414_CR111","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"key":"1414_CR112","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43:5047\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615.","journal-title":"Eur Heart J"},{"key":"1414_CR113","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088\u201393. https:\/\/doi.org\/10.1161\/01.CIR.98.19.2088.","journal-title":"Circulation"},{"key":"1414_CR114","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.atherosclerosis.2011.08.015","volume":"219","author":"A Brautbar","year":"2011","unstructured":"Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, et al. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011;219:737\u201342. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.08.015.","journal-title":"Atherosclerosis"},{"key":"1414_CR115","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/00008571-200412000-00005","volume":"14","author":"C Foucher","year":"2004","unstructured":"Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, et al. Response to micronized fenofibrate treatment is associated with the peroxisome???proliferator-activated receptors alpha G\/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics. 2004;14:823\u20139. https:\/\/doi.org\/10.1097\/00008571-200412000-00005.","journal-title":"Pharmacogenetics"},{"key":"1414_CR116","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.atherosclerosis.2014.03.010","volume":"234","author":"F Gao","year":"2014","unstructured":"Gao F, Ballantyne C, Ma L, Virani SS, Keinan A, Brautbar A. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia. Atherosclerosis. 2014;234:249\u201353. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.03.010.","journal-title":"Atherosclerosis"},{"key":"1414_CR117","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cpt.798","volume":"103","author":"DM Rotroff","year":"2018","unstructured":"Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, et al. Genetic variants in HSD17B3, SMAD3, and IPO11 impact circulating lipids in response to fenofibrate in individuals with type 2 diabetes. Clin Pharmacol Ther. 2018;103:712\u201321. https:\/\/doi.org\/10.1002\/cpt.798.","journal-title":"Clin Pharmacol Ther"},{"key":"1414_CR118","doi-asserted-by":"publisher","first-page":"e48663","DOI":"10.1371\/journal.pone.0048663","volume":"7","author":"S Aslibekyan","year":"2012","unstructured":"Aslibekyan S, Goodarzi MO, Frazier-Wood AC, Yan X, Irvin MR, Kim E, et al. Variants Identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate. PLoS ONE. 2012;7:e48663. https:\/\/doi.org\/10.1371\/journal.pone.0048663.","journal-title":"PLoS ONE"},{"key":"1414_CR119","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/s41591-025-03533-w","volume":"31","author":"NA Marston","year":"2025","unstructured":"Marston NA, Kamanu FK, Melloni GEM, Schnitzler G, Hakim A, Ma RX, et al. Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering. Nat Med. 2025;31:963\u20139. https:\/\/doi.org\/10.1038\/s41591-025-03533-w.","journal-title":"Nat Med"},{"key":"1414_CR120","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/S0140-6736(14)61730-X","volume":"385","author":"JL Mega","year":"2015","unstructured":"Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield MJ, Devlin JJ, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385:2264\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(14)61730-X.","journal-title":"Lancet"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-026-01414-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-026-01414-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:51:08Z","timestamp":1779353468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-026-01414-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":120,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s11883-026-01414-2","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}